ENAapplication/xmlftp.sra.ebi.ac.uk/vol1/fastq/SRR815/001/SRR8159331/SRR8159331.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/004/SRR8159344/SRR8159344.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/007/SRR8159357/SRR8159357.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/000/SRR8159350/SRR8159350.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/009/SRR8159319/SRR8159319.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/005/SRR8159325/SRR8159325.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/008/SRR8159338/SRR8159338.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/003/SRR8159363/SRR8159363.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/003/SRR8159343/SRR8159343.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/000/SRR8159330/SRR8159330.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/002/SRR8159362/SRR8159362.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/004/SRR8159324/SRR8159324.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/008/SRR8159318/SRR8159318.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/007/SRR8159337/SRR8159337.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/006/SRR8159356/SRR8159356.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/007/SRR8159327/SRR8159327.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/000/SRR8159320/SRR8159320.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/006/SRR8159346/SRR8159346.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/006/SRR8159336/SRR8159336.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/005/SRR8159355/SRR8159355.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/005/SRR8159345/SRR8159345.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/007/SRR8159317/SRR8159317.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/004/SRR8159354/SRR8159354.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/004/SRR8159364/SRR8159364.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/006/SRR8159326/SRR8159326.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/009/SRR8159329/SRR8159329.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/006/SRR8159316/SRR8159316.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/005/SRR8159335/SRR8159335.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/002/SRR8159322/SRR8159322.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/001/SRR8159341/SRR8159341.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/005/SRR8159315/SRR8159315.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/007/SRR8159347/SRR8159347.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/008/SRR8159328/SRR8159328.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/003/SRR8159353/SRR8159353.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/004/SRR8159334/SRR8159334.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/001/SRR8159321/SRR8159321.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/000/SRR8159340/SRR8159340.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/004/SRR8159314/SRR8159314.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/009/SRR8159359/SRR8159359.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/002/SRR8159342/SRR8159342.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/001/SRR8159361/SRR8159361.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/009/SRR8159349/SRR8159349.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/002/SRR8159352/SRR8159352.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/003/SRR8159333/SRR8159333.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/002/SRR8159332/SRR8159332.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/000/SRR8159360/SRR8159360.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/009/SRR8159339/SRR8159339.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/008/SRR8159358/SRR8159358.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/003/SRR8159323/SRR8159323.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/008/SRR8159348/SRR8159348.fastq.gzftp.sra.ebi.ac.uk/vol1/fastq/SRR815/001/SRR8159351/SRR8159351.fastq.gzprimaryOK200Genomics3181 SW Sam Jackson Park Road, Knight Cancer Institute, OHSUhttps://www.ebi.ac.uk/ena/browser/view/PRJNA503877This SuperSeries is composed of the SubSeries listed below. Overall design: Refer to individual SeriesENAMyelocytic, leukemia, xC/EBP, CSF3R, C/EBP-alpha, acute myeloblastic leukemia, acute myelocytic leukemia, acute Nonlymphocytic leukemia, acute myelogenous leukemia, acute myeloid leukemia not otherwise categorized, GCSFR, acute non lymphoblastic leukemia, acute myeloid leukaemia NOS, DBPCEP, acute myeloblastic leukaemia, acute myelogenous leukaemia, acute myeloid leukemia not otherwise specified, G-CSF receptor activity, impaired, somatic, acute myelogenous leukemias, autosomal dominant, partial functionality, AML, dysfunctional, Csfgr, acute granulocytic leukemia, acute non lymphoblastic leukaemia, G-CSF receptor, CEBP, acute myeloid leukemia NOS, NOS, acute myeloid, unclassified acute myeloid leukemia, M4/M4Eo subtype, myeloid leukemia, acute myeloid leukaemia (AML), CEBPA, C/EBP, acute, acute myeloid leukaemia not otherwise categorised, unclassified AML, hematopoeitic - acute Myleogenous leukaemia (AML), Leukemia, granulocyte colony stimulating factor receptor activity, Cebp, dysfunction, susceptibility to, acute myeloid leukemia, C/EBPalpha, acute myeloid leukaemia, acute granulocytic leukaemia, C|EBP-alpha, lacks function of type, acute myelocytic leukaemia, AML - acute myeloid leukemia, CD114, low functionality, hematopoeitic - acute Myleogenous leukemia (AML), C|ebpalpha, having decreased function, C/EBP alpha, unclassified acute myeloid leukaemia, acute myeloid leukemia (AML), acute Nonlymphocytic leukaemia, G-CSF-R, reduced survival in, AML - acute myeloid leukaemia, acute nonlymphocytic leukemia, ANLL, CBF-A, myelocytic, acute nonlymphocytic leukaemia, acute myeloid leukaemia not otherwise specified, AML - acute Myeloid Leukemia., somatic mutation, C/ebpalpha, acute myelogenousMyelocytic, leukemia, xC/EBP, CSF3R, C/EBP-alpha, acute myeloblastic leukemia, acute myelocytic leukemia, acute Nonlymphocytic leukemia, acute myelogenous leukemia, acute myeloid leukemia not otherwise categorized, GCSFR, acute non lymphoblastic leukemia, acute myeloid leukaemia NOS, DBPCEP, acute myeloblastic leukaemia, acute myelogenous leukaemia, acute myeloid leukemia not otherwise specified, G-CSF receptor activity, impaired, somatic, acute myelogenous leukemias, autosomal dominant, partial functionality, AML, dysfunctional, Csfgr, acute granulocytic leukemia, acute non lymphoblastic leukaemia, G-CSF receptor, CEBP, acute myeloid leukemia NOS, NOS, acute myeloid, unclassified acute myeloid leukemia, M4/M4Eo subtype, myeloid leukemia, acute myeloid leukaemia (AML), CEBPA, C/EBP, acute, acute myeloid leukaemia not otherwise categorised, unclassified AML, hematopoeitic - acute Myleogenous leukaemia (AML), Leukemia, granulocyte colony stimulating factor receptor activity, Cebp, dysfunction, susceptibility to, acute myeloid leukemia, C/EBPalpha, acute myeloid leukaemia, acute granulocytic leukaemia, C|EBP-alpha, lacks function of type, acute myelocytic leukaemia, AML - acute myeloid leukemia, CD114, low functionality, hematopoeitic - acute Myleogenous leukemia (AML), C|ebpalpha, having decreased function, C/EBP alpha, unclassified acute myeloid leukaemia, acute myeloid leukemia (AML), acute Nonlymphocytic leukaemia, G-CSF-R, reduced survival in, AML - acute myeloid leukaemia, acute nonlymphocytic leukemia, ANLL, CBF-A, myelocytic, acute nonlymphocytic leukaemia, acute myeloid leukaemia not otherwise specified, AML - acute Myeloid Leukemia., somatic mutation, C/ebpalpha, acute myelogenous0.00.00.00.00.0falseCEBPA Dysfunction Intiates CSF3R Mutant Acute Myeloid Leukemia Through Disruption of Myeloid Lineage EnhancersCEBPA Dysfunction Intiates CSF3R Mutant Acute Myeloid Leukemia Through Disruption of Myeloid Lineage Enhancers2022-05-122019-12-04PRJNA503877GSE1221663178453832471953